Plain-English translation of NCT07444723 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing two advanced imaging scans called 18F-Fluorocholine PET/MRI and PET/CT that are designed to help doctors locate parathyroid tumors more accurately. The scans use a special tracer (18F-Fluorocholine) that highlights parathyroid tumors so they're easier to find. The trial will compare how well these new scans work compared to the standard imaging test currently used.
Finding parathyroid tumors can be difficult with standard imaging, and some patients have multiple tumors or rare inherited forms of parathyroid disease that are especially hard to locate. This trial aims to see if the new imaging approach can find tumors more reliably, which could help doctors plan better surgery and improve patient outcomes.
You likely qualify if…
You likely don't qualify if…
You would receive an injection of the tracer (18F-Fluorocholine) and then undergo two imaging scans—a PET/MRI scan and a PET/CT scan—to allow doctors to see where your parathyroid tumors are located. You would also have the standard imaging test (4D-CT) so the researchers can compare how well all three methods work. After these scans, you would proceed with parathyroid surgery at the NIH Clinical Center as planned.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States